Josep R. Germà

1.5k total citations
29 papers, 1.1k citations indexed

About

Josep R. Germà is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Josep R. Germà has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Surgery and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Josep R. Germà's work include Testicular diseases and treatments (5 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (4 papers). Josep R. Germà is often cited by papers focused on Testicular diseases and treatments (5 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (4 papers). Josep R. Germà collaborates with scholars based in Spain, United Kingdom and France. Josep R. Germà's co-authors include Gabriel Capellá, Francesc Viñals, Miguel A. Peinado, Xavier García del Muro, Berta Laquente, E. Marcuello, Albert Figueras, Sara González, Ramón Mangues and Enric Condom and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Josep R. Germà

28 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Josep R. Germà Spain 17 524 360 331 330 177 29 1.1k
Cosimo Sacco Italy 18 527 1.0× 276 0.8× 213 0.6× 389 1.2× 209 1.2× 59 1.2k
Kanwal Raghav United States 19 568 1.1× 221 0.6× 369 1.1× 349 1.1× 160 0.9× 52 1.1k
Giuseppe Fornarini Italy 22 597 1.1× 245 0.7× 305 0.9× 562 1.7× 74 0.4× 125 1.3k
Ho‐Kyung Chun South Korea 21 991 1.9× 182 0.5× 597 1.8× 314 1.0× 219 1.2× 44 1.3k
Alessandra Ravaioli Italy 19 913 1.7× 210 0.6× 161 0.5× 533 1.6× 170 1.0× 107 1.3k
C.J.H. van de Velde Netherlands 21 788 1.5× 109 0.3× 604 1.8× 389 1.2× 178 1.0× 39 1.5k
Shalini Singh United States 18 662 1.3× 275 0.8× 134 0.4× 370 1.1× 199 1.1× 38 1.1k
Elide Matano Italy 14 907 1.7× 228 0.6× 260 0.8× 863 2.6× 86 0.5× 48 1.5k
F. Safi Germany 19 786 1.5× 224 0.6× 405 1.2× 236 0.7× 163 0.9× 47 1.1k
Adam Pawinski Norway 21 583 1.1× 414 1.1× 705 2.1× 558 1.7× 60 0.3× 69 1.6k

Countries citing papers authored by Josep R. Germà

Since Specialization
Citations

This map shows the geographic impact of Josep R. Germà's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josep R. Germà with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josep R. Germà more than expected).

Fields of papers citing papers by Josep R. Germà

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josep R. Germà. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josep R. Germà. The network helps show where Josep R. Germà may publish in the future.

Co-authorship network of co-authors of Josep R. Germà

This figure shows the co-authorship network connecting the top 25 collaborators of Josep R. Germà. A scholar is included among the top collaborators of Josep R. Germà based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josep R. Germà. Josep R. Germà is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Germà, Josep R., et al.. (2016). Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer. Journal of Medical Economics. 20(1). 1–7. 28 indexed citations
2.
Figueras, Albert, M.A. Arbós, Maite Quiles, et al.. (2013). The impact of KRAS mutations on VEGF-A production and tumour vascular network. BMC Cancer. 13(1). 125–125. 31 indexed citations
3.
Parker, Christopher, S. Pascoe, Aleš Chodacki, et al.. (2012). A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer. European Urology. 63(2). 189–197. 133 indexed citations
4.
Pernas, Sònia, Miguel Gil‐Gil, María Ochoa de Olza, et al.. (2012). Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice. Breast Cancer Research and Treatment. 134(3). 1161–1168. 14 indexed citations
5.
6.
Oaknin, Ana, Maria-Pilar Barretina-Ginesta, Laura Jiménez, et al.. (2010). CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD). International Journal of Gynecological Cancer. 20(1). 87–91. 6 indexed citations
7.
Piulats, Josep M., Xavier García del Muro, August Vidal, et al.. (2009). Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors. Clinical Cancer Research. 15(10). 3384–3395. 55 indexed citations
8.
Laquente, Berta, Cristina Lacasa, M. Morell, et al.. (2008). Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Molecular Cancer Therapeutics. 7(3). 638–647. 55 indexed citations
9.
Laquente, Berta, Francesc Viñals, & Josep R. Germà. (2007). Metronomic chemotherapy: an antiangiogenic scheduling. Clinical & Translational Oncology. 9(2). 93–98. 52 indexed citations
10.
Mollevı́, David G., Teresa Serrano, M. Morell, et al.. (2007). Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis. 28(6). 1241–1246. 29 indexed citations
11.
Corral, Julieta, et al.. (2007). Impacto presupuestario de los nuevos fármacos para el tratamiento del cáncer colorrectal. Medicina Clínica. 129(4). 134–136. 9 indexed citations
12.
Majem, Margarita, Maica Galán, Montserrat Muñoz-Mateu, et al.. (2007). The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity. Clinical & Translational Oncology. 9(12). 784–788. 20 indexed citations
13.
14.
Muro, Xavier García del, Enric Condom, Francesc Vigués, et al.. (2004). p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined‐modality approach. Cancer. 100(9). 1859–1867. 59 indexed citations
15.
Muro, Xavier García del, E. Marcuello, Josep Gumà, et al.. (2002). Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. British Journal of Cancer. 86(3). 326–330. 34 indexed citations
16.
Muro, Xavier García del, A. Torregrosa, Juan José Múñoz, et al.. (2000). Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer. European Journal of Cancer. 36(3). 357–362. 91 indexed citations
17.
Móra, Josefina, et al.. (1995). Alpha-fetoprotein-concanavalin a binding as a marker to discriminate between germ cell tumours and liver diseases. European Journal of Cancer. 31(13-14). 2239–2242. 14 indexed citations
18.
Germà, Josep R., Marta Llanos, Josep Tabernero, & Josefina Móra. (1993). False elevations of alpha-fetoprotein associated with liver dysfunction in germ cell tumors. Cancer. 72(8). 2491–2494. 41 indexed citations
19.
Germà, Josep R., et al.. (1988). Sequential combination chemotherapy for malignant germ cell tumors of the ovary. Cancer. 61(5). 913–918. 11 indexed citations
20.
Germà, Josep R., et al.. (1987). False elevations of human chorionic gonadotropin associated to latrogenic hypogonadism in gonadal germ cell tumors. Cancer. 60(10). 2489–2493. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cosimo Sacco Breakdown of academic impact, for papers by Kanwal Raghav Breakdown of academic impact, for papers by Giuseppe Fornarini Breakdown of academic impact, for papers by Ho‐Kyung Chun Breakdown of academic impact, for papers by Alessandra Ravaioli Breakdown of academic impact, for papers by C.J.H. van de Velde Breakdown of academic impact, for papers by Shalini Singh Breakdown of academic impact, for papers by Elide Matano Breakdown of academic impact, for papers by F. Safi Breakdown of academic impact, for papers by Adam Pawinski
Rankless by CCL
2026